medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2000, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2000; 47 (2)

Gatifloxacina 'a new fluoroquinolone' versus other antimicrobians against respiratory vias pathogens

Giono-Cerezo S, García-Zaldívar P, Tapia-Nava A, Peredo-López VMA

Language: Spanish
References: 17
Page: 100-106
PDF size: 103.68 Kb.


ABSTRACT

Introduction: Increasing resistance of respiratory pathogens to several antimicrobials has been reported in Mexico. Gatifloxacin (GAT) is a new 8-methoxy fluoroquinolone with an excellent activity the same in vivo as in vitro against prevalent respiratory pathogens. Material and methods: To assess GAT activity, 211 respiratory pathogens strains were tested by disk diffusion according to NCCLS for a total of: 36 Haemophilus influenzae, 32 Streptococcus pneumoniae, 27 Moraxella catarrhalis, 55 Streptococcus pyogenes and 61 Staphylococcus aureus strains, isolated from ambulatory and hospitalized patients with respiratory tract infections from August 1999 to January 2000 in Mexico City. Results: Gatifloxacin presented an excellent antimicrobial activity from range of 97-100 % of susceptibility against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus. These pathogens presented a high resistance to ampicillin (22 to 98 %). Conclusions: The results obtained confirm that Gatifloxacin has a high susceptibility against main respiratory vias pathogens compared with other antimicrobials of common use. It is recommended to periodically realize an strict local monitoring on the susceptibility profiles, in order to practice a better selection for the antimicrobial therapeutic.


REFERENCES

  1. Giono CS. Agentes bacterianos de infecciones respiratorias. En: García ML, Giono CS, Pacheco CR, Escobar GA, Valdespino GJL, editores. Infecciones respiratorias agudas y crónicas. México: INDRE-SSa; 1994. p. 401-414.

  2. Levy SB. The challenge of antibiotic resistance. Scientific American 1998; March:32-39.

  3. Neu HC. The crisis in antibiotic resistance. Science 1992;257: 1064-1072.

  4. Weinberg GA, Spitzer E, Murray P, Ghafoor A, Montgomery J, Tupasi T, Granoff, The BOSTID Haemophilus influenzae Susceptibility Study Group. Antimicrobial susceptibility patterns of Haemophilus influenzae from children in eleven developing nations. WHO Bull 1990;68:179-184.

  5. Barriga AG, Castillo TN, Alarcón ON, Rojas ML. Susceptibilidad in vitro de microorganismos causales de infecciones graves en pacientes hospitalizados. Rev Mex Patol Clin 1996;43(1):43-46.

  6. Calderón E, Conde G, Gatica R, Rivera R, Hernando N, Barriga G, Hill J, Romero G. Antimicrobial resistance among bacterial isolates from children. Current Therap Res 1993;54(5):482-492.

  7. Giono CS, Carrillo JL. Uso y abuso de los antibióticos. Investigación Hoy (IPN) 1997;75:20-27.

  8. Sifuentes OJ, Donis HJ, Arredondo GJL, Escalante RO, Macías A, Muñoz JM, Ontiveros L, Novoa FO, Rodríguez SR, Rolón AL, Soriano B, Tinoco JC. Informe sobre resistencia bacteriana. Estudio piloto en seis centros de México. Rev Panam Infectol 1999; Supl 1:S45-S47.

  9. Ramírez JA, Nguyen T, Tellier G, Coppola G, Bettis R, Dolmann A, St-Pierre C, Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs. twice-daily clarithromycin. J Respir Dis 1999;20 Suppl november (11A):S40-S48.

  10. Ball AP, Tillotson G. Lower respiratory tract infection therapy-the role of ciprofloxacin. J Intern Med Res 1995;23:315-327.

  11. Barriga AG, Alarcón O, Montaño de Plata C. Susceptibilidad in vitro de bacterias causales de infección adquirida en la comunidad. Rev Enf Inf Ped Mex 1997; 11(42):52-58.

  12. Jacobs MR. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices. Am J Med 1999;106(5A):19S-25S.

  13. Investigator’s Brochure. Gatifloxacin (BMS-206584, Am-1155). Bristol-Myers Squibb Company, November 1996.

  14. Ramírez A, Molina J, Dolmann A, Fogarty C, DeAbate A, Breen J, Skuba K. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial result. J Respir Dis 1999;20 Suppl November (11A):S30-S39.

  15. National Committee for Clinical Laboratory Standards. Document M100-s9;18(1-2)2nd Wayne Penn USA 1999.

  16. Armelagos GJ. Redes planetarias para los microbios. Mundo Cientifico 1999;197:57-60.

  17. Giono CS. Haemophilus influenzae. En: García ML, Giono CS, Pacheco CR, Escobar GA, Valdespino GJL, editores. Infecciones respiratorias agudas y crónicas. México: INDRE-SSa; 1994. p. 445-450.




2020     |     www.medigraphic.com